Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis) - Full Text View

Sponsor:	Children's Hospital of Philadelphia
Collaborator:	Cystic Fibrosis Foundation
Information provided by:	Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:	NCT00590538

Purpose

The purpose of this research study is to test a new combination of medicines, Phenylbutyrate and Genistein, to determine if they could be used to treat cystic fibrosis (CF). The most common genetic mutation found in patients with CF is called Delta F508. Due to this mutation, there is a lack of salt (chloride) movement in your nose, sinuses, lungs, intestines, pancreas and sweat glands. This lack of movement causes the clinical manifestations of the disease.

Although Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases, Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. When used together, both drugs may be able to restore normal chloride and salt (water) movements in body organs and glands in people with CF.

We will be studying salt and water movement in the nose by a technique called nasal transepithelial potential difference (NPD).

Condition	Intervention	Phase
Cystic Fibrosis	Drug: Sodium 4-Phenylbutyrate Drug: Genistein (Unconjugated Isoflavones 100) Drug: Placebo	Phase I Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Basic Science
Official Title:	A Pilot Trial of Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygous Cystic Fibrosis Patients

Resource links provided by NLM:

Genetics Home Reference related topics: cystic fibrosis

MedlinePlus related topics: Cystic Fibrosis

Drug Information available for: PTI-G 4660 Genistein Sodium phenylbutyrate

U.S. FDA Resources

Further study details as provided by Children's Hospital of Philadelphia:

Primary Outcome Measures:

Change in Voltage (mVolt) in Nasal Epithelium [ Time Frame: Baseline and 2 weeks ] [ Designated as safety issue: No ]
The basis of analysis for the primary outcome measure will be the comparison of data from both the standard CF Nasal Potential Difference (NPD) Protocol compared to a modified NPD protocol including the perfusion of Genistein.

The NPD response will be compared from baseline to after study drug. NPD responses will then be compared between the Phenylbutrate group and the placebo group.

Secondary Outcome Measures:

Change in FEV1 (Forced Expiratory Volume in 1 Second) in Spirometry. [ Time Frame: baseline and 2 weeks ] [ Designated as safety issue: Yes ]
Outcome measure will be obtained from standard Pulmonary Function testing.
Change in FVC (Forced Vital Capacity)in Spirometry. [ Time Frame: baseline and 2 weeks ] [ Designated as safety issue: Yes ]
Outcome measure will be obtained from standard Pulmonary Function testing.
Number of Participants With Adverse Events [ Time Frame: up to 2 weeks ] [ Designated as safety issue: Yes ]
Adverse Events will be assessed and outcome measure obtained by completion of Interval history, physical and mental status examinations of every participant.
Number of Participants With Abnormal Laboratory Safety Tests [ Time Frame: up to 2 weeks ] [ Designated as safety issue: Yes ]
Outcome measure will be obtained by completion of routine metabolic and hematological laboratory parameters for every participant. Metabolic testing willl include a CMP (comprehensive metabolic panel, ALT (alanine aminotransferase test), GGT (gamma-glutamyl transpeptidase), and Uric Acid; Hematological testing will include a complete blood count (CBC), and partial thromboplastin (PT/PTT).

Enrollment:	9
Study Start Date:	February 2003
Study Completion Date:	December 2008
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Phenylbutyrate The standard oral adult dose is 20 g/day for 4 days. Every participant will receive Genistein during the NPD.	Drug: Sodium 4-Phenylbutyrate The standard oral adult dose is 20 g/day (tablets) for 4 days. Other Name: 4PBA Drug: Genistein (Unconjugated Isoflavones 100) Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure. Other Name: PTI G-4660, 87% Genistein
Placebo Comparator: Placebo The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.	Drug: Genistein (Unconjugated Isoflavones 100) Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure. Other Name: PTI G-4660, 87% Genistein Drug: Placebo The placebo is given to match the active comparator for four days.

Detailed Description:

This protocol is investigating novel pharmaceutical agents (Phenylbutyrate and Genistein), which are aimed at improving the physiologic function of mutant Cystic Fibrosis Transmembrane conductance Regulator (CFTR). CFTR is absent or dysfunctional in cystic fibrosis. Nasal epithelial CFTR function will be assessed by the NPD procedure.

We will test the hypotheses that:

Phenylbutyrate given orally for 4 days will be safe in adult Delta F508- heterozygous subjects with CF and will result in small improvements in nasal epithelial CFTR function.
Topical administration of Genistein to the nasal epithelia of Phenylbutyrate treated Delta F508-heterozygous CF subjects will be safe and lead to augmentation of the improved nasal epithelial CFTR function observed during Phenylbutyrate treatment, but not during placebo treatment.

Study Flow If eligibility is confirmed at the screening visit, there will be an additional 3 outpatient visits over a 1-2 week period, lasting 2-4 hours each.

Visit 1, all study related safety evaluations will be completed. There will also be a Nasal Potential Difference (NPD) measurement performed. To measure nasal potentials, or voltages, a small butterfly needle will be placed in the skin of the forearm and connected by a thin plastic tube to a monitoring device. A very small soft plastic catheter or tube will be placed against the inner surface of the nose. This catheter will pump a very small amount of saltwater onto the nose and it will connect to the monitoring machine. This machine senses very small electrical voltages that are generated by the body. It does not and cannot send electricity or shocks to the subject. A measurement is made and then the fluid pumped into the nose is changed to one containing a drug called amiloride. Amiloride changes the makeup of salt transported in the nose and reduces the electrical voltage. Then the fluid is changed to saltwater that does not contain chloride. The fluid is then changed to one that has the drug isoproterenol. Isoproterenol causes the cells in subjects without CF to move chloride. The doses of amiloride and isoproterenol used in this study are much lower than those typically used in patients for other reasons. Finally, the fluid will be changed to one containing the experimental drug Genistein.

Subject will then be randomized and given a 4-day supply of the study drug.

Visit 2, subject will have safety evaluations and NPD performed in the same manner as previous visit. No more study drug after this visit.

Visit 3, subject will have safety evaluations and NPD performed without the perfusion of Genistein.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Able to communicate with pertinent staff, able to understand and willing to comply with the requirements of the trial, and able and willing to give informed consent.
Willing to practice a reliable and study-accepted method of contraception during the study.
Diagnosis of cystic fibrosis consisting of both:
1. clinical manifestations of cystic fibrosis and
2. either cystic fibrosis genotype heterozygous for Delta F508 with a second identified CFTR mutation, or cystic fibrosis genotype with one Delta F508 allele and one unidentified allele and sweat sodium or chloride > 60 mEq/L
Oxyhemoglobin saturation greater than or equal to 92% while breathing room air

Exclusion Criteria:

Underlying diseases likely to limit life span and/or increase risk of complications:
1. Cancer requiring treatment in the past 5 years, with the exception of cancers that have been cured, or in the opinion of the investigator, carry a good prognosis such as non-melanoma skin cancer, papillary thyroid carcinoma, and cervical cancer in situ.
2. GI disease
i. Inflammatory bowel disease requiring treatment in the past year ii. elevations in ALT or AST levels to greater than 3 times the upper limit of normal
Conditions or behaviors likely to affect the conduct of the study
1. Current or anticipated participation in another intervention research project
2. Recent (with 2 months) sinus surgery or nasal polypectomy
3. Currently pregnant or less than 3 months post-partum
4. Currently nursing or within 6 weeks of having completed nursing
5. Unwilling to undergo pregnancy testing or to report possible or confirmed pregnancy promptly during the course of the study
6. Unwilling to use a reliable contraceptive method for two months after the completion of the study.
7. Major psychiatric disorder, which, in the opinion of the investigators, would impede conduct of the study, e.g., alcoholism
8. Other condition, which, in the opinion of the investigators, would impede conduct of the study.
Glucocorticoids other than topical, ophthalmic, and inhaled preparations.
Conditions that would place the patient at an increased risk for complications:
1. Pneumothorax within the last 12 months
2. Uncontrolled diabetes
3. Asthma or allergic bronchopulmonary aspergillosis requiring systemic glucocorticoid therapy within the last two months
4. Sputum culture growing a pathogen that does not have in vitro sensitivity to at least two types of antibiotics which could be administered to the patient
5. History of major hemoptysis: (Greater than 240 mL of blood within a 24-hour period within the last 12 months).
Medication use or conditions not specifically mentioned above, including severe or end stage CF lung disease, that may serve as criteria for exclusion at the discretion of the investigators.
History of significant cardiovascular disease, such as myocardial infarction, congestive heart failure, unstable arrhythmia, or uncontrolled hypertension.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00590538

Locations

United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

Children's Hospital of Philadelphia

Cystic Fibrosis Foundation

Investigators

Principal Investigator:

Ronald Rubenstein, M.D., PhD.

Children's Hospital of Philadelphia

More Information

No publications provided

Responsible Party:	Ronald Rubenstein, M.D., PhD., The Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:	NCT00590538 History of Changes
Other Study ID Numbers:	2002-10-3023, RUBENS01A0
Study First Received:	December 27, 2007
Results First Received:	November 15, 2010
Last Updated:	June 29, 2011
Health Authority:	United States: Food and Drug Administration; United States: Institutional Review Board

Additional relevant MeSH terms:

Cystic Fibrosis
Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes
4-phenylbutyric acid
Genistein
Antineoplastic Agents
Therapeutic Uses

Pharmacologic Actions
Phytoestrogens
Estrogens, Non-Steroidal
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anticarcinogenic Agents
Protective Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 12, 2012